Cellply banked €7.15M in a funding round led by ENEA Tech e Biomedical to scale its analytical tools for cancer treatment development. The investment includes the conversion of a SAFE previously held by CDP Venture Capital through its Fondo Rilancio. A small final allocation of this round remains open to selected additional investors.
Based in Bologna, the deeptech company provides analytical systems for the characterisation of cell-based medicines and immunotherapies. Its core technology allows researchers to assess the potency and persistence of therapeutic cells at single-cell resolution. These tools are used to validate the quality and efficacy of advanced therapy medicinal products (ATMPs) during the discovery and manufacturing stages.
The company's primary product, VivaCyte, is an automated platform that combines patented microfluidic technology with AI-powered image analysis. By automating the transition from sample preparation to data processing, the system is designed to replace manual laboratory workflows. This enables pharmaceutical companies to accelerate the development of complex biotherapeutics while reducing the risk of human error in quality control.
Cellply will use the capital to support international commercial expansion and increase its presence in global markets. The funding also earmarks resources for the continued development of its quality control software and hardware. The company's focus on automating biological analysis reflects a growing trend in the European biotech sector to integrate hardware and data science to industrialise cell therapy production.
Originally reported by EU-Startups Daily.